Literature DB >> 28584020

KITD816V Induces SRC-Mediated Tyrosine Phosphorylation of MITF and Altered Transcription Program in Melanoma.

Bengt Phung1,2,3, Julhash U Kazi1, Alicia Lundby4, Kristin Bergsteinsdottir2, Jianmin Sun1, Colin R Goding5, Göran Jönsson3, Jesper V Olsen4, Eiríkur Steingrímsson6, Lars Rönnstrand7.   

Abstract

The oncogenic D816V mutation of the KIT receptor is well characterized in systemic mastocytosis and acute myeloid leukemia. Although KITD816V has been found in melanoma, its function and involvement in this malignancy is not understood. Here we show that KITD816V induces tyrosine phosphorylation of MITF through a triple protein complex formation between KIT, MITF, and SRC family kinases. In turn, phosphorylated MITF activates target genes that are involved in melanoma proliferation, cell-cycle progression, suppression of senescence, survival, and invasion. By blocking the triple protein complex formation, thus preventing MITF phosphorylation, the cells became hypersensitive to SRC inhibitors. We have therefore delineated a mechanism behind the oncogenic effects of KITD816V in melanoma and provided a rationale for the heightened SRC inhibitor sensitivity in KITD816V transformed cells.Implications: This study demonstrates that an oncogenic tyrosine kinase mutant, KITD816V, can alter the transcriptional program of the transcription factor MITF in melanoma Mol Cancer Res; 15(9); 1265-74. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28584020     DOI: 10.1158/1541-7786.MCR-17-0149

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  9 in total

1.  Risk of solid cancer in patients with mast cell activation syndrome: Results from Germany and USA.

Authors:  Gerhard J Molderings; Thomas Zienkiewicz; Jürgen Homann; Markus Menzen; Lawrence B Afrin
Journal:  F1000Res       Date:  2017-10-26

2.  Repurposing Ponatinib as a Potent Agent against KIT Mutant Melanomas.

Authors:  Yong Han; Ziyue Gu; Jing Wu; Xiaojuan Huang; Rong Zhou; Chaoji Shi; Wenjie Tao; Lizhen Wang; Yanan Wang; Guoyu Zhou; Jiang Li; Zhiyuan Zhang; Shuyang Sun
Journal:  Theranostics       Date:  2019-03-16       Impact factor: 11.556

Review 3.  MITF-the first 25 years.

Authors:  Colin R Goding; Heinz Arnheiter
Journal:  Genes Dev       Date:  2019-05-23       Impact factor: 11.361

Review 4.  Melanoma and Mastocytosis.

Authors:  Aleksandra Vojvodic; Tatjana Vlaskovic-Jovicevic; Petar Vojvodic; Jovana Vojvodic; Mohamad Goldust; Zorica Peric-Hajzler; Dusica Matovic; Goran Sijan; Nenad Stepic; Uwe Wollina; Massimo Fioranelli; Michael Tirant; Van Thuong Nguyen; Torello Lotti
Journal:  Open Access Maced J Med Sci       Date:  2019-08-30

5.  Protein tyrosine phosphatase receptor type E (PTPRE) regulates the activation of wild-type KIT and KIT mutants differently.

Authors:  Shaoting Zhang; Liangying Zhang; Zongying Jiang; Yue Guo; Hui Zhao; Jianmin Sun
Journal:  Biochem Biophys Rep       Date:  2021-03-02

6.  3, 3'- (3, 5-DCPBC) Down-Regulates Multiple Phosphokinase Dependent Signal Transduction Pathways in Malignant Melanoma Cells through Specific Diminution of EGFRY1086 Phosphorylation.

Authors:  Abhijit Basu; M Iqbal Choudhary; Karin Scharffetter-Kochanek
Journal:  Molecules       Date:  2022-02-09       Impact factor: 4.411

7.  PPP6C, a serine-threonine phosphatase, regulates melanocyte differentiation and contributes to melanoma tumorigenesis through modulation of MITF activity.

Authors:  Carolyn R Maskin; Renuka Raman; Yariv Houvras
Journal:  Sci Rep       Date:  2022-04-02       Impact factor: 4.379

8.  Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis.

Authors:  Farshad Farshidfar; Kahn Rhrissorrakrai; Chaya Levovitz; Cong Peng; James Knight; Antonella Bacchiocchi; Juan Su; Mingzhu Yin; Mario Sznol; Stephan Ariyan; James Clune; Kelly Olino; Laxmi Parida; Joerg Nikolaus; Meiling Zhang; Shuang Zhao; Yan Wang; Gang Huang; Miaojian Wan; Xianan Li; Jian Cao; Qin Yan; Xiang Chen; Aaron M Newman; Ruth Halaban
Journal:  Nat Commun       Date:  2022-02-23       Impact factor: 17.694

9.  Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib.

Authors:  Guangrong Zhu; Jun Shi; Shaoting Zhang; Yue Guo; Ling Huang; Hui Zhao; Yideng Jiang; Jianmin Sun
Journal:  Cell Biosci       Date:  2020-02-12       Impact factor: 7.133

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.